溴隐亭治疗非急症性泌乳素型垂体腺瘤的临床效果

Clinical Effect of Bromocriptine in the Treatment of Non-acute Prolactin Pituitary Adenoma

目的:研究溴隐亭治疗非急症性泌乳素型垂体腺瘤的临床效果。方法:选择2016年1月~2019年12月内蒙古医科大学第三附属医院神经外科和妇产科收治的120例非急症性泌乳素型垂体腺瘤患者,随机分为两组。对照组给予手术治疗,观察组在对照组基础上口服溴隐亭治疗,起始时每天的剂量为2.5 mg,给药3~5 d后,逐渐将每天的剂量增加至7.5 mg,分成2~3次服用,维持给药3个月。比较两组治疗前、治疗1个月和3个月,比较两组的血清泌乳素水平和症状评分,并观察两组的心理领域、社会领域、环境领域和生理领域评分。结果:观察组的有效率明显高于对照组(P<0.05);治疗1个月和3个月,两组非急症性泌乳素型垂体腺瘤患者的血清泌乳素水平均明显降低(P<0.05),且观察组的血清泌乳素水平明显低于对照组(P<0.05);治疗1个月和3个月,两组的泌乳素型垂体腺瘤症状评分均明显降低(P<0.05),且观察组的泌乳素型垂体腺瘤症状评分明显低于对照组(P<0.05);治疗后,两组的心理领域、社会领域、环境领域和生理领域评分明显升高(P<0.05),且观察组的心理领域、社会领域、环境领域和生理领域评分明显高于对照组(P<0.05)。结论:肿瘤切除术后联合服用溴隐亭能更好的改善非急症性泌乳素型垂体腺瘤患者的症状,降低血清泌乳素水平,提高生活质量,值得推广。

Objective: To investigate the effect of bromocriptine in the treatment of non-acute prolactin pituitary adenoma.Methods: A total of 120 patients with non-acute prolactin-type pituitary adenoma who were admitted to the Department of Neurosurgery and Obstetrics and Gynecology ofthe Third Affiliated Hospital of Inner Mongolia Medical University from January 2016 to December2019 were randomly divided into two groups. The control group was given surgical treatment, and the observation group was treated with bromocriptine on the basis of the control group. The initial daily dose was 2.5 mg. After 3 to 5 days of administration, the daily dose was gradually increased to 7.5 mg and divided into 2 to Take 3 times, maintain the medicine for 3 months. Compare the two groups before treatment, 1 month and 3 months of treatment, compare the serum prolactin levels and symptom scores of the two groups, and observe the psychological, social, environmental and physiological scores of the two groups. Results: The effective rate of the observation group was significantly higher than control group(P<0.05). After 1 month and 3 months of treatment, the serum PRL levels of non-acute prolactin pituitary adenoma patients in the two groups were significantly reduced(P<0.05), and the serum PRL levels in the observation group were significantly lower than those in the control group(P<0.05). After 1 month and 3 months of treatment, the prolactin pituitary adenoma symptom scores in both groups were significantly reduced(P<0.05), and the prolactin pituitary adenoma symptom scores in the observation group were significantly lower than those in the control group(P<0.05). After treatment, the scores of the psychological,social, environmental, and physiological fields in the two groups increased significantly(P<0.05), and the scores of the psychological,social, environmental, and physiological fields in the observation group were significantly higher than those in the control group(P<0.05). Conclusion: The combined use of bromocriptine after tumor resection can better improve the symptoms of patients with non-acute prolactin-type pituitary adenomas, reduce serum PRL levels, and improve quality of life, which is worth promoting.